Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | CCKBR | P32239 | 11/20 | 0.59 |
| ▸ | CCKAR | P32238 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700399 | 1.00 | OPRM1 (0.61) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23700396 | 1.00 | OPRM1 (0.61) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23700278 | 0.96 | OPRM1 (0.65) | OPRM1CCKBROPRD1OPRK1 | |
| SCHEMBL23700276 | 0.96 | OPRM1 (0.65) | OPRM1CCKBROPRD1OPRK1 | |
| SCHEMBL23700274 | 0.96 | OPRM1 (0.65) | OPRM1CCKBROPRD1OPRK1 | |
| SCHEMBL23700366 | 0.95 | OPRM1 (0.58) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23710309 | 0.95 | OPRM1 (0.58) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23700359 | 0.95 | OPRM1 (0.58) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23700363 | 0.95 | OPRM1 (0.58) | OPRM1CCKBRCCKAROPRD1OPRK1 | |
| SCHEMBL23700432 | 0.94 | OPRM1 (0.56) | OPRM1CCKBRCCKAROPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238225-A1 | PEPTIDOMIMETIC INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) | PIN1, PPIA, PPIE | OPRM1 3964/4885CCKBR 4137/4885CCKAR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.